Full-Time

Medical Science Liaison

Epilepsy/Neuroscience

Posted on 9/12/2025

Jazz Pharmaceuticals

Jazz Pharmaceuticals

1,001-5,000 employees

Biopharmaceuticals focused on neuroscience and oncology

No salary listed

Madrid, Spain

Hybrid

Field-based role with 60% to 70% time spent in the field.

Category
Medical, Clinical & Veterinary (2)
,
Requirements
  • Scientific Graduate with a higher qualification (e.g. PhD, Pharm D, MSc etc.)
  • Proven track record of success in KOL management with an established network of contacts within the Pharmaceutical industry, and ability to build contacts, work in the field with external stakeholders.
  • Significant Medical Science Liaison experience and strong knowledge of the pharma/biotech industry
  • Clear understanding of MSL roles and responsibilities and Medical Affairs activities, including publication planning, medical information and advisory boards.
  • Excellent interpersonal communication and relationship building skills.
  • Strong multi-tasking, time management and organisational skills for a busy environment with a demonstrated ability to prioritise multiple assignments and deliver results while meeting deadlines.
  • Demonstrated ability to lead and coordinate meetings.
  • Demonstrated strong understanding of clinical research trial design.
  • Excellent verbal, written communication and presentation skills. Ability to clearly articulate complex scientific concepts in one-to-one and group settings.
  • Proactive approach with proven ability to take initiative and work both independently and as part of a team.
  • Proven track record in delivering on projects at the country level, with both internal and external stakeholders, also with the ability to manage partners and work with ‘dotted line’ matrix team flows.
  • Strong organisational abilities, with an ability to prioritise tasks, and place the customer needs at the forefront of activities.
  • Strong IT skills, with an ability to create informative and factual scientific documents and presentations, to distill complex data in a timely manner.
  • Full understanding of the compliance environment and ability to design activities to fit within local regulatory framework and understanding of approval processes.
  • Fluent in English and Spanish.
Responsibilities
  • Identifying national, regional and local KOLs in the area of Neurology & Rare Diseases, and developing and maintaining long-term collaborative relationships.
  • Developing synergistic relationships with KOLs to expand research, advisory and educational partnership opportunities and developing synergistic scientific exchange opportunities between with internal and external colleagues.
  • Delivering regional engagement plans with KOLs, based upon insights into their specialties and interests in specific areas of improving patient care.
  • Engaging with specific Clinical and Scientific experts and Institutions/Organisations in the territory, through appropriate high-level scientific support for research activities, publications, education, consulting and other Medical Affairs initiatives.
  • Understanding the needs of HCPs and developing insights through listening and observing the challenges faced in the treatment of serious diseases in paediatric and adult neurology therapy areas.
  • Possess an in-depth knowledge of Jazz medicines, answering questions from HCPs, communicating salient facts in a clear, factual and non-promotional manner.
  • Providing reactive medical support and scientific medical presentations within the therapeutic area to external stakeholders as needed.
  • Becoming the ‘go to’ person for Clinician’s field of Rare Disease Neurology and cannabinoid therapies.
  • Work with a diverse range of functions (e.g. Medical Information, Pharmacovigilance) to provide the optimal all-round medical service provision to partners.
  • Developing country medical projects in collaboration with HCPs (round table meetings, diagnosis workshops, rare disease forums, etc) within the defined therapeutic area.
  • Providing medical support and International Congress, including lead, design and delivery of medical function activities, and working with commercial colleagues in the appropriate frameworks.
  • Running appropriate advisory board panel meetings, to seek answers to questions specific to the needs and understanding of the Jazz Medical function business.
  • Coordinating interactions with academic societies, research groups and other national organisations.
  • Exploring novel educational opportunities with healthcare associations and ancillary healthcare professionals.
  • Spending the majority of time in a field-based role, developing projects through self-motivation, and the identification of appropriate opportunities to help improve HCP education and patient care.
  • Ensuring pharmacovigilance excellence, through adverse event reporting monitoring and liaising with HCPs to gather additional Drug Safety information as requested.
  • Maintaining a strict delineation/definition with non-medical colleagues.
  • Maintaining an understanding and application of local regulation in all activities.
  • Participating in scientific and medical training of sales colleagues, and Jazz partner organisations.
  • Responding to complex scientific enquires from the field, received through the commercial force. Providing scientific and medical support for internal meetings and projects as needed.
  • Working within defined SOPs across functions for optimal team delivery for Jazz business.
  • Identifying and supporting Phase II-IV sites as required and working with the clinical team as major liaison for trial sites.
  • Receiving and processing Investigator Initiated Trials (IIT) from the environment, and working with the medical and clinical team to ensure all IIT are providing appropriate support.
  • Identify, understand, distill and communicate new and complex data from inside Jazz and from the external environment.
  • Produce educational materials, using various media, and lead on internal education and teaching activities within the environment of the EU medical team.
  • Providing field updates regarding topics of interest for creation and/or updating of Standard Response Letters.
  • Contribute to the National and International Medical team for development of Medical team ways of working, and aligned execution of the EU Medical strategy.
Desired Qualifications
  • Experience in the therapy areas of epilepsy or neurology in general, is desirable.

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Simplify Jobs

Simplify's Take

What believers are saying

  • Epidiolex generated $1.1B in 2025 sales, up 9% YoY, with patents protected to late 2030s.
  • Q1 2026 revenue hit $1.1B, up 19% YoY, prompting Raymond James target raise to $239 on May 7.
  • Chimerix acquisition adds dordaviprone for H3 K27M-mutant glioma, PDUFA August 18, 2025.

What critics are saying

  • Generic competition erodes Xywav revenue as it replaces Xyrem, decelerating growth to 5.5% annually.
  • Dordaviprone fails FDA approval on August 18, 2025 PDUFA, wasting $935M Chimerix acquisition.
  • $850M exchangeable notes due 2030 dilute equity at $153.05 exchange price amid EPS decline.

What makes Jazz Pharmaceuticals unique

  • Jazz Pharmaceuticals focuses on neuroscience and oncology for rare diseases with limited treatments.
  • Xywav offers 92% less sodium than Xyrem, approved July 21, 2020, for narcolepsy in patients aged 7+.
  • Epidiolex, acquired via $7.2B GW Pharma deal in 2021, treats Lennox-Gastaut and Dravet syndromes.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Intellectia.AI
Mar 4th, 2026
Day One Biopharmaceuticals shares surge 28% on takeover rumours from Ipsen and Jazz

Day One Biopharmaceuticals shares surged 28% amid acquisition rumours, with Jazz Pharmaceuticals and Ipsen cited as potential acquirers. Eight out of nine analysts rate the stock as "buy" or higher, with an average price target of $22.75 representing over 75% upside. The company reported Q4 2025 revenue of $52.8 million for its drug Ojemda, an 83% year-over-year increase. Full-year 2025 net product revenue reached $155.4 million, up 172%. Despite a net loss of $107.3 million in 2025, Day One projects 2026 US revenue between $225 million and $250 million. The biopharmaceutical firm ended 2025 with $441.1 million in cash and no debt. Retail sentiment on Stocktwits remained "extremely bullish" as speculation about a potential merger intensified.

Yahoo Finance
Feb 28th, 2026
Jazz Pharmaceuticals' CBD drug Epidiolex hits $1B in sales — time to buy the stock?

Jazz Pharmaceuticals' cannabidiol therapy Epidiolex has surpassed $1 billion in annual product sales, achieving blockbuster status. The drug, which treats seizures associated with rare epilepsy syndromes, generated $1.1 billion in 2025, representing approximately a quarter of Jazz's total revenues and marking 9% year-over-year growth. Jazz acquired Epidiolex through its $7.2 billion purchase of GW Pharmaceuticals in 2021. The company has resolved nearly all outstanding generic litigation, extending patent protection into the late 2030s and reducing competitive threats. Management sees significant growth potential in adult patients, particularly within long-term care settings. The company is investing in diagnostic tools and patient-support programmes to expand adoption beyond paediatric use. Jazz's portfolio also includes successful neuroscience and oncology products.

Yahoo Finance
Feb 25th, 2026
Jazz Pharmaceuticals shares jump 13.5% on strong Q4 results with $1.2B revenue

Jazz Pharmaceuticals shares rose 13.5% after reporting fourth-quarter 2025 revenue of $1.2 billion, up 10.1% year-on-year and exceeding analyst estimates. Adjusted earnings of $6.64 per share also beat expectations. The company's operating margin expanded to 21.2% from 17.5% in the prior year, demonstrating improved operational efficiency. However, full-year revenue guidance fell short of consensus estimates. Investors appeared to focus on the strong quarterly performance despite the mixed outlook. The shares reached a new 52-week high of $196.34, bringing year-to-date gains to 13.4%. The stock has experienced significant volatility, with 12 moves greater than 5% over the past year.

Jazz Pharmaceuticals
Jun 23rd, 2025
Jazz Pharmaceuticals and Azur Pharma Combine to Create Jazz Pharmaceuticals plc | Jazz Pharmaceuticals plc

DUBLIN , Jan. 18, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the closing of the business combination of Jazz Pharmaceuticals, Inc. and Azur Pharma plc .  The two companies have combined to create Jazz Pharmaceuticals plc , a specialty biopharmaceutical company

CityBiz
Mar 5th, 2025
Jazz Pharmaceuticals Acquires Chimerix for $935M

Jazz Pharmaceuticals is set to acquire Chimerix for $935 million, paying $8.55 per share in cash. The acquisition, expected to close in Q2 2025, will add Chimerix's lead asset, dordaviprone, to Jazz's portfolio. Dordaviprone is a treatment for H3 K27M-mutant diffuse glioma, a rare brain tumor. The FDA has accepted its NDA for accelerated approval, with a PDUFA date of August 18, 2025. Jazz plans to fund the deal through existing cash and investments.

INACTIVE